VERA Vera Therapeutics, Inc. Insider Trading

VERA CEO Marshall Fordyce sells 46.2K shares for $1,956,187.12 via 10b5-1 plan; holds 152.0K post-sale.

Marshall Fordyce, VERA's President and CEO, executed 4 separate sales totaling 46,250 shares for $1,956,187.12 on 2026-07-07, reducing his holdings by 23.3% to 152.0K shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-01-09, meaning it was scheduled rather than discretionary. The company reported a negative net income of $-121,032,000.00 over its most recent full fiscal year, indicating ongoing operational losses. Notably, the insider's prior same-ticker trades at VERA show 30-day price declines (ranging from -8.2% to -11.3%), establishing a pattern where subsequent price movement has favored the sell decision, though these outcomes remain early and the current 90-day windows are not yet complete.

CEO Marshall Fordyce sold 18,500 shares ($701.8K) at VERA via scheduled 10b5-1 plan on 2026-06-23.

Marshall Fordyce, President and CEO, executed 2 separate sales totaling 18,500 shares for $701,769.25 as part of a pre-arranged 10b5-1 trading plan adopted on 2026-01-09, reducing his holdings from 216,744 shares to 198,244 shares. The company reported net income of -$121,032,000 for its most recent full fiscal year and currently trades at $39.51, down 29.5% from its 52-week high of $56.05. Fordyce's prior trades at VERA have resulted in average 30-day declines of -8.2% to -13.1%, though these scheduled sales reflect pre-determined execution rather than discretionary timing decisions. Given the company's unprofitability, the ongoing scheduled nature of the plan adopted in January, and the CEO's continued material stake of 198,244 shares post-transaction, this filing merits monitoring for whether subsequent disclosures signal changes in the company's operational trajectory.

VERA President and CEO Fordyce Marshall sells ~18,500 shares for $680K as stock trades well below its 52-week high; all five prior VERA sales saw subsequent declines.

Fordyce Marshall, President and CEO of Vera Therapeutics, is liquidating equity with this sale of approximately 18,500 shares, reducing his stake by roughly 8%. The stock is currently trading well below its 52-week high, having declined over the recent quarter, while the company remains unprofitable with significant operating losses. What makes this sale notable is Marshall's own track record at this company: all five of his prior open-market sales at Vera have been followed by stock declines, suggesting he has demonstrated consistent skill at timing exits before downward pressure. This is his sixth and seventh open-market sale at Vera in the past three years, continuing a pattern of steady, well-timed dispositions rather than panic selling or one-off exits. However, the underlying fundamentals remain weak—the company is not profitable, and the cumulative losses suggest significant operational challenges ahead.

VERA CEO Fordyce Marshall sold 22,951 shares for $1,011,050.81 under pre-arranged 10b5-1 plan

Fordyce Marshall, PRESIDENT AND CEO of Vera Therapeutics, executed 3 separate sales totaling 22,951 shares for $1,011,050.81 on 2026-04-14, reducing his holdings from 258,195 shares to 235,244 shares (an 8.9% reduction). The sales were conducted at prices ranging from $43.66 to $45.51, with a blended average price of $44.05. Critically, this transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-01-09, meaning the sales were scheduled and non-discretionary rather than a reflection of current market judgment. The scheduled nature of these sales limits inference about directional conviction; this represents execution of a predetermined divestiture plan rather than a discretionary market decision by the CEO.

VERA Director Enright purchases 5,882 shares at $42.50; extends prior accumulation pattern with 4 consecutive buys at ticker.

Patrick Enright, a Director at Vera Therapeutics, purchased 5,882 shares for $249,985.00 at $42.50 on 2025-12-11, establishing an initial position in the stock. This transaction marks the fifth consecutive buy from this insider at VERA: he has made four prior purchases at this ticker on 2025-06-23 and 2025-06-24, all of which generated positive 90-day returns (ranging from +16.8% to +22.6%). The current purchase occurs at $42.50 versus today's price of $49.21, placing the transaction in the lower half of the 52-week range ($18.86–$49.80). Against his cross-ticker track record of 8 prior buys (average 90d return -6.0%), his same-ticker history at VERA stands out notably: 4 of 4 prior buys were well-timed at the 90-day mark, contrasting with a 66.67% 90d win rate across all holdings. However, the company reported a net loss of $-80,293,000.00 in its most recent full fiscal year, presenting a fundamental backdrop of ongoing unprofitability that bears on the context of this accumulation.

Director ENRIGHT PATRICK G bought 250,000 shares for $5,277,311.42 across 4 transactions on 2025-06-23 and 2025-06-24.

Patrick G. Enright, a director at Vera Therapeutics, executed 4 separate purchases totaling 250,000 shares for $5,277,311.42 on June 23–24, 2025, raising his holdings from 3,346,593 to 3,596,593 shares—a 7.5% increase in his position at an average price of $21.11. This is notable in light of Vera's recent financial distress: the company reported a full-year net income of $-51,694,000.00 and is currently trading at $23.31, down 53.2% from its 52-week high of $49.75 despite a 30-day rally of +18.7%. Enright's cross-ticker trading history shows 2 prior open-market buys with a 0.00% 90-day win rate and an average 90-day return of -57.4%, indicating that his past purchase decisions have not preceded favorable near-term price performance. The size and timing of this $5.3M accumulation in a loss-making biotech company under a director warrant scrutiny, particularly given the asymmetry between his purchase activity and his demonstrated difficulty timing entries across his portfolio.

VERA CEO Fordyce Marshall sells 17,500 shares for $730,535.37 via scheduled 10b5-1 plan; holdings drop to 143.6K shares

Fordyce Marshall executed 3 separate sales totaling 17,500 shares for $730,535.37 on 2025-01-08, reducing his holdings from 161.1K to 143.6K shares. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2024-04-23, meaning it was scheduled rather than discretionary. The blended average price across the three sales was $41.74. As a routine scheduled liquidation by the CEO, this filing reflects pre-planned capital management rather than a signal driven by current market conditions or strategic conviction.

VERA CEO Fordyce Marshall sold 17,500 shares for $753,679.56 on 2024-12-18 under pre-arranged 10b5-1 plan.

Fordyce Marshall, President and CEO of Vera Therapeutics, executed 5 separate sales totaling 17,500 shares for $753,679.56 on 2024-12-18, reducing his holdings from 161,103 shares to 143,603 shares. This sale was conducted under a pre-arranged 10b5-1 trading plan adopted on 2024-04-23, making it a scheduled transaction rather than a discretionary decision. The blended average transaction price was $43.07 across the five sales. As a scheduled, pre-planned divestment, this filing reflects adherence to an established trading schedule and does not carry timing or conviction signals that would attach to discretionary insider sales.

CEO Fordyce Marshall sells 17,500 shares for $821,523.29 via pre-arranged 10b5-1 plan

Fordyce Marshall, President and CEO of Vera Therapeutics, executed 4 separate sales totaling 17,500 shares for $821,523.29 on 2024-12-11 at a blended average price of $46.94. This transaction reduced his holdings from 103,442 shares to 85,942 shares, a reduction of 16.9% of his pre-transaction position. The sales were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2024-04-23, meaning the timing and volume were scheduled in advance rather than discretionary. As a Rule 10b5-1 transaction, the sale represents a pre-planned reduction rather than a real-time market decision.

CEO Fordyce Marshall sells 19,375 shares at $47.98 blended avg for $929.6K; pre-arranged 10b5-1 plan from April 2024.

Fordyce Marshall, President and CEO of Vera Therapeutics, executed 5 separate sales totaling 19,375 shares for $929,560.27 on 2024-11-25 under a 10b5-1 trading plan adopted on 2024-04-23. The sales reduced his holdings from 105,317 shares to 85,942 shares, representing an 18.4% reduction in position size. Because this transaction is part of a scheduled 10b5-1 plan rather than a discretionary trade, it reflects a predetermined divestment schedule established seven months prior and provides no signal regarding his current assessment of the company's near-term prospects.